H Cody Meissner

Summary

Affiliation: Tufts-New England Medical Center
Country: USA

Publications

  1. ncbi Measles vaccines and the potential for worldwide eradication of measles
    H Cody Meissner
    Division of Pediatric Infectious Disease, Tufts New England Medical Center, University School of Medicine, 750 Washington St, Boston, MA 02111, USA
    Pediatrics 114:1065-9. 2004
  2. ncbi Hematologic effects of linezolid in young children
    H Cody Meissner
    Pediatric Infectious Diseases, New England Medical Center, Tufts University School of Medicine, 750 Washington Street, NEMCH Box 321, Boston, MA 02111, USA
    Pediatr Infect Dis J 22:S186-92. 2003
  3. ncbi Unpredictable patterns of viral respiratory disease in children
    H Cody Meissner
    Division of Pediatric Infectious Disease, New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
    Pediatrics 113:1814-6. 2004
  4. ncbi Influenza vaccines: a pediatric perspective
    H Cody Meissner
    Pediatric Infectious Disease, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Curr Opin Pediatr 19:58-63. 2007
  5. ncbi Reducing the impact of viral respiratory infections in children
    H Cody Meissner
    Division of Pediatric Infectious Disease, Tufts New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
    Pediatr Clin North Am 52:695-710, v. 2005
  6. ncbi Annual variation in respiratory syncytial virus season and decisions regarding immunoprophylaxis with palivizumab
    H Cody Meissner
    Pediatric Infectious Disease Division, Tufts-New England Medical Center, Tufts University School of Medicine, 750 Washington St, Boston, MA 02111, USA
    Pediatrics 114:1082-4. 2004
  7. ncbi Elimination of rubella from the United States: a milestone on the road to global elimination
    H Cody Meissner
    Division of Pediatric Infectious Disease, New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
    Pediatrics 117:933-5. 2006
  8. ncbi Kawasaki syndrome: where are the answers?
    H Cody Meissner
    Division of Pediatric Infectious Diseases, New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
    Pediatrics 112:672-6. 2003
  9. ncbi Selected populations at increased risk from respiratory syncytial virus infection
    H Cody Meissner
    New England Medical Center, Tufts University School of Medicine, Boston, MA, USA
    Pediatr Infect Dis J 22:S40-4; discussion S44-5. 2003
  10. ncbi Technical report: Reduction of the influenza burden in children
    Margaret B Rennels
    Pediatrics 110:e80. 2002

Detail Information

Publications21

  1. ncbi Measles vaccines and the potential for worldwide eradication of measles
    H Cody Meissner
    Division of Pediatric Infectious Disease, Tufts New England Medical Center, University School of Medicine, 750 Washington St, Boston, MA 02111, USA
    Pediatrics 114:1065-9. 2004
    ..To address the possibility of worldwide control of measles, efforts to ensure high immunization rates among people in both developed and developing countries must be sustained...
  2. ncbi Hematologic effects of linezolid in young children
    H Cody Meissner
    Pediatric Infectious Diseases, New England Medical Center, Tufts University School of Medicine, 750 Washington Street, NEMCH Box 321, Boston, MA 02111, USA
    Pediatr Infect Dis J 22:S186-92. 2003
    ..In adults linezolid treatment for >/=2 weeks has been associated with reversible hematopoietic suppression, primarily thrombocytopenia...
  3. ncbi Unpredictable patterns of viral respiratory disease in children
    H Cody Meissner
    Division of Pediatric Infectious Disease, New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
    Pediatrics 113:1814-6. 2004
  4. ncbi Influenza vaccines: a pediatric perspective
    H Cody Meissner
    Pediatric Infectious Disease, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Curr Opin Pediatr 19:58-63. 2007
    ..I will review the current recommendations regarding use of trivalent, inactivated influenza vaccine and live, attenuated influenza vaccine...
  5. ncbi Reducing the impact of viral respiratory infections in children
    H Cody Meissner
    Division of Pediatric Infectious Disease, Tufts New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
    Pediatr Clin North Am 52:695-710, v. 2005
    ..Particular emphasis is placed on prevention and control of viral disease through the use of vaccines and antiviral agents. Evolution of new viral pathogens, such as avian influenza virus and the SARS-CoV, are discussed...
  6. ncbi Annual variation in respiratory syncytial virus season and decisions regarding immunoprophylaxis with palivizumab
    H Cody Meissner
    Pediatric Infectious Disease Division, Tufts-New England Medical Center, Tufts University School of Medicine, 750 Washington St, Boston, MA 02111, USA
    Pediatrics 114:1082-4. 2004
  7. ncbi Elimination of rubella from the United States: a milestone on the road to global elimination
    H Cody Meissner
    Division of Pediatric Infectious Disease, New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
    Pediatrics 117:933-5. 2006
  8. ncbi Kawasaki syndrome: where are the answers?
    H Cody Meissner
    Division of Pediatric Infectious Diseases, New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
    Pediatrics 112:672-6. 2003
  9. ncbi Selected populations at increased risk from respiratory syncytial virus infection
    H Cody Meissner
    New England Medical Center, Tufts University School of Medicine, Boston, MA, USA
    Pediatr Infect Dis J 22:S40-4; discussion S44-5. 2003
    ....
  10. ncbi Technical report: Reduction of the influenza burden in children
    Margaret B Rennels
    Pediatrics 110:e80. 2002
    ..This report contains a summary of the influenza virus, protective immunity, disease burden in children, diagnosis, vaccines, and antiviral agents...
  11. ncbi Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections
    H Cody Meissner
    Pediatrics 112:1447-52. 2003
    ..Because of the large number of infants born after 32 to 35 weeks' gestation and because of the high cost, immunoprophylaxis should be considered for this category of preterm infants only if 2 or more risk factors are present...
  12. ncbi Prevention of influenza: recommendations for influenza immunization of children, 2007-2008
    Joseph A Bocchini
    Pediatrics 121:e1016-31. 2008
    ..However, oseltamivir and zanamivir can be prescribed for treatment or chemoprophylaxis, because influenza A and B strains remain susceptible...
  13. ncbi Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease
    Timothy F Feltes
    Ohio State University and The Children s Hospital, 700 Children s Drive, ED622, Columbus, OH 43205, USA
    J Pediatr 143:532-40. 2003
    ..To evaluate the safety, tolerance, and efficacy of palivizumab in children with hemodynamically significant congenital heart disease (CHD)...
  14. ncbi Risk of severe respiratory syncytial virus disease, identification of high risk infants and recommendations for prophylaxis with palivizumab
    H Cody Meissner
    Pediatr Infect Dis J 23:284-5. 2004
  15. ncbi Respiratory syncytial virus infection and recurrent wheezing: a complex relationship
    H Cody Meissner
    J Pediatr 151:6-7. 2007
  16. ncbi Varicella prevention in the United States: a review of successes and challenges
    Mona Marin
    Centers for Disease Control and Prevention, 1600 Clifton Rd, NE, MS A 47, Atlanta, GA 30333, USA
    Pediatrics 122:e744-51. 2008
    ..The objective of this review was to summarize the US experience with the 1-dose varicella vaccination program, present the evidence considered for the policy change, and outline future challenges of the program...
  17. ncbi Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children
    Henry Shinefield
    The University of California San Francisco, USA
    Pediatr Infect Dis J 24:670-5. 2005
    ..A second injection of MMRV resulted in a significant boost in VZV antibody. This boost may translate into enhanced immunogenicity against varicella, which is known to correlate with increased protection...
  18. ncbi Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children
    Robert B Belshe
    Saint Louis University, St Louis, Missouri 63110, USA
    J Infect Dis 190:2096-103. 2004
    ..Both vaccines were immunogenic, and antibody responses were similar between the monovalent groups and the combination group. Combined RSV/PV3 vaccine is feasible for simultaneous administration, and further studies are warranted...
  19. ncbi Prevalence of superantigen-secreting bacteria in patients with Kawasaki disease
    Donald Y M Leung
    Department of Pediatrics, The National Jewish Medical and Research Center and University of Colorado Health Sciences Center, Denver, USA
    J Pediatr 140:742-6. 2002
    ..However, future studies should further examine the potential role of Vbeta2-stimulatory superantigens (TSST-1 and SPEB/SPEC) in KD...
  20. ncbi Immunoprophylaxis with RespiGam
    H Cody Meissner
    Pediatrics 113:629. 2004
  21. ncbi Exposure to nontraditional pets at home and to animals in public settings: risks to children
    Larry K Pickering
    Pediatrics 122:876-86. 2008
    ....